Skip to main content
. 2022 Sep 20;9:991586. doi: 10.3389/fcvm.2022.991586

FIGURE 2.

FIGURE 2

Risk assessment of the patients (n = 62) in the efficacy set at baseline and follow-up. Change in (A) WHO functional class (FC); and (B) the number of low risk criteria after selexipag treatment.